Missed GME or NVDA? Don’t Miss the Next One.​
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
HQY Stock Forecast 2025-2026
$100.08
Current Price
$8.88B
Market Cap
Buy 13
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to HQY Price Targets
+29.9%
To High Target of $130.00
+10.9%
To Median Target of $111.00
-6.1%
To Low Target of $94.00
HQY Price Momentum
+1.9%
1 Week Change
+16.3%
1 Month Change
+25.4%
1 Year Change
+4.3%
Year-to-Date Change
-13.4%
From 52W High of $115.59
+53.9%
From 52W Low of $65.01
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching HealthEquity (HQY) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on HQY and similar high-potential opportunities.
Latest HQY Stock Price Targets & Analyst Predictions
Based on our analysis of 24 Wall Street analysts, HQY has a bullish consensus with a median price target of $111.00 (ranging from $94.00 to $130.00). The overall analyst rating is Strong Buy (9.1/10). Currently trading at $100.08, the median forecast implies a 10.9% upside. This outlook is supported by 13 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from David Larsen at BTIG, projecting a 29.9% upside. Conversely, the most conservative target is provided by David Roman at Goldman Sachs, suggesting a 6.1% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
HQY Analyst Ratings
13
Buy
1
Hold
0
Sell
HQY Price Target Range
Low
$94.00
Average
$111.00
High
$130.00
Current: $100.08
Latest HQY Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for HQY.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 16, 2025 | Keybanc | Scott Schoenhaus | Overweight | Maintains | $100.00 |
| Apr 11, 2025 | Barrington Research | Alexander Paris | Outperform | Maintains | $112.00 |
| Mar 27, 2025 | Goldman Sachs | David Roman | Neutral | Maintains | $94.00 |
| Mar 25, 2025 | Raymond James | C. Gregory Peters | Strong Buy | Upgrade | $115.00 |
| Mar 24, 2025 | Keybanc | Scott Schoenhaus | Overweight | Maintains | $110.00 |
| Mar 19, 2025 | Barrington Research | Alexander Paris | Outperform | Maintains | $112.00 |
| Mar 14, 2025 | Barrington Research | Alexander Paris | Outperform | Maintains | $112.00 |
| Feb 26, 2025 | Wells Fargo | Stan Berenshteyn | Overweight | Maintains | $125.00 |
| Feb 25, 2025 | Raymond James | C. Gregory Peters | Outperform | Maintains | $120.00 |
| Dec 10, 2024 | JMP Securities | Constantine Davides | Market Outperform | Maintains | $107.00 |
| Dec 10, 2024 | RBC Capital | Sean Dodge | Outperform | Maintains | $105.00 |
| Dec 4, 2024 | Mizuho | Steven Valiquette | Outperform | Initiates | $126.00 |
| Dec 2, 2024 | Barrington Research | Alexander Paris | Outperform | Maintains | $120.00 |
| Nov 15, 2024 | Goldman Sachs | David Roman | Neutral | Initiates | $108.00 |
| Nov 14, 2024 | BTIG | David Larsen | Buy | Maintains | $130.00 |
| Nov 13, 2024 | B of A Securities | Allen Lutz | Buy | Maintains | $120.00 |
| Sep 20, 2024 | Barrington Research | Alexander Paris | Outperform | Maintains | $105.00 |
| Sep 5, 2024 | Barrington Research | Outperform | Maintains | $0.00 | |
| Sep 4, 2024 | RBC Capital | Sean Dodge | Outperform | Reiterates | $92.00 |
| Sep 4, 2024 | JMP Securities | Constantine Davides | Market Outperform | Reiterates | $105.00 |
HealthEquity Inc. (HQY) Competitors
The following stocks are similar to HealthEquity based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
HQY
HealthEquity
mkt cap
8.46B
HealthEquity Inc. (HQY) Financial Data
HealthEquity Inc. has a market capitalization of $8.88B with a P/E ratio of 94.0x. The company generates $1.20B in trailing twelve-month revenue with a 8.1% profit margin.
Revenue growth is +18.8% quarter-over-quarter, while maintaining an operating margin of +14.2% and return on equity of +4.7%.
Valuation Metrics
Market Cap
$8.88B
Enterprise Value
$9.36B
P/E Ratio
94.0x
PEG Ratio
27.8x
Price/Sales
7.4x
Growth & Margins
Revenue Growth (YoY)
+18.8%
Gross Margin
+60.6%
Operating Margin
+14.2%
Net Margin
+8.1%
EPS Growth
+18.8%
Financial Health
Cash/Price Ratio
+3.4%
Current Ratio
3.1x
Debt/Equity
52.4x
ROE
+4.7%
ROA
+3.8%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
HealthEquity Inc. (HQY) Business Model
About HealthEquity Inc.
What They Do
Administers health savings accounts and consumer benefits.
Business Model
The company generates revenue by managing health savings accounts (HSAs) and offering consumer-directed benefits. It leverages a technology-driven platform to provide users with tools and insights for effective financial management of healthcare expenses, thereby enhancing its value proposition in the healthcare financial sector.
Additional Information
HealthEquity plays a crucial role in the healthcare ecosystem by connecting consumers with healthcare providers and financial services. With a strong presence and support for millions of consumers, the company is strategically positioned to benefit from the growing demand for consumer-driven financial solutions in healthcare.
Company Information
Sector
Healthcare
Industry
Health Information Services
Employees
3,105
CEO
Mr. Scott R. Cutler J.D.
Country
United States
IPO Year
2014
Website
www.healthequity.comHealthEquity Inc. (HQY) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
MD vs. HQY: Which Stock Is the Better Value Option?
MD vs. HQY: Which Stock Is the Better Value Option?
May 21, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Rosen Law Firm is investigating potential securities claims against HealthEquity, Inc. (NASDAQ: HQY) for allegedly misleading business information. Affected shareholders may seek compensation without upfront costs.
Why It Matters
Allegations against HealthEquity regarding misleading information could lead to legal actions, impacting stock performance and shareholder value, which may affect investment decisions.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Investors in the Medical Services sector may find Pediatrix Medical Group (MD) and HealthEquity (HQY) to be potential stocks for value opportunities.
Why It Matters
The comparison of Pediatrix Medical Group and HealthEquity highlights potential value opportunities in the Medical Services sector, influencing investment decisions and portfolio strategies.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Rosen Law Firm is investigating potential securities claims for HealthEquity, Inc. (NASDAQ: HQY) over allegations of misleading business information to investors.
Why It Matters
Allegations of misleading information can lead to legal risks and financial losses for HealthEquity, potentially impacting its stock price and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Rosen Law Firm is investigating potential securities claims for HealthEquity, Inc. (NASDAQ:HQY) shareholders over allegations of misleading business information. Affected investors may seek compensation with no upfront costs.
Why It Matters
Allegations against HealthEquity for misleading information could lead to significant legal claims, impacting stock value and investor confidence, potentially resulting in compensation for affected shareholders.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
New York City reported news on May 13, 2025, but the details of the announcement were not provided in the excerpt. Further information is needed for investor relevance.
Why It Matters
The news excerpt lacks specific details about economic events or company performance, making it difficult to ascertain its relevance to investment decisions.
Source: Accesswire
Market Sentiment:
Neutral
HealthEquity Announces First Quarter Earnings Release Date Presentations at Investor Conferences
13 days ago
Quick Summary
HealthEquity, Inc. (NASDAQ: HQY) will release its Q1 fiscal 2026 financial results on June 3, 2025, after market close, followed by a conference call at 4:30 p.m. ET.
Why It Matters
HealthEquity's upcoming financial results and conference call may impact its stock price and investor sentiment, providing insights into its performance and future outlook in the HSA market.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About HQY Stock
What is HealthEquity Inc.'s (HQY) stock forecast for 2025?
Based on our analysis of 24 Wall Street analysts, HealthEquity Inc. (HQY) has a median price target of $111.00. The highest price target is $130.00 and the lowest is $94.00.
Is HQY stock a good investment in 2025?
According to current analyst ratings, HQY has 13 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $100.08. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for HQY stock?
Wall Street analysts predict HQY stock could reach $111.00 in the next 12 months. This represents a 10.9% increase from the current price of $100.08. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is HealthEquity Inc.'s business model?
The company generates revenue by managing health savings accounts (HSAs) and offering consumer-directed benefits. It leverages a technology-driven platform to provide users with tools and insights for effective financial management of healthcare expenses, thereby enhancing its value proposition in the healthcare financial sector.
What is the highest forecasted price for HQY HealthEquity Inc.?
The highest price target for HQY is $130.00 from David Larsen at BTIG, which represents a 29.9% increase from the current price of $100.08.
What is the lowest forecasted price for HQY HealthEquity Inc.?
The lowest price target for HQY is $94.00 from David Roman at Goldman Sachs, which represents a -6.1% decrease from the current price of $100.08.
What is the overall HQY consensus from analysts for HealthEquity Inc.?
The overall analyst consensus for HQY is bullish. Out of 24 Wall Street analysts, 13 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $111.00.
How accurate are HQY stock price projections?
Stock price projections, including those for HealthEquity Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 23, 2025 3:19 AM UTC